The Hydropothecary Corp. gets price target raise at Beacon Securities

Expansion plans have Beacon Securities analyst Vahan Ajamian feeling bullish about The Hydropothecary Corp. (The Hydropothecary Corp. Stock Quote, Chart, News: TSXV:THCX).

This morning, Hydropothecary announced it had acquired 78 acres of land next to its current Gatineau facility. The company said it intends to construct a one-million square foot facility that will be capable of producing 108,000 kg of dried cannabis per year.

“Hydropothecary is boldly stepping forward to take the lead in the Canadian cannabis industry,” said CEO Sebastien St-Louis. “With our expansion, we are moving into industrial agri-nomics, robotic technology, fully automated systems and the cannabis plant as a THC bioreactor. Once legalization of the adult-use recreational market becomes a reality, Hydropothecary will be ready.

Ajamian calls this “a very significant development”. He says it not a big leap of logic to imagine that Hydropoathecary has some visibility on the future.

“We do not believe the company would embark on such a massive expansion without a sense as to where it would be selling the product and at approximately what price,” the analyst says. “For context, extrapolating the three MOUs from New Brunswick, we calculate the size of the Quebec market at 144,000 kg with a retail value of $1.5B.”

In a research update to clients today, Ajamian maintained his “Buy” rating on The Hydropothecary Corp., but raised his one-year price target from $4.00 to $8.50, implying a return of 107 per cent at the time of publication.

Ajamian thinks Hydropothecary will generate EBITDA of negative $4.5-million on revenue of $11.3-million in fiscal 2018. He expects those numbers will improve to EBITDA of positive $6.1-million on a topline of $35.7-million the following year.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: thcx
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Chorus Aviation price target trimmed at CIBC

Following first quarter results, CIBC analyst Kevin Chiang has lowered his price target on Chorus Aviation (Chorus Aviation Stock Quote,… [Read More]

27 mins ago

Is Magellan Aerospace stock a buy?

Its first quarter results are in the books and Paradigm Capital analyst J Marvin Wolff thinks there is money to… [Read More]

23 hours ago

Phunware is undervalued, Roth says

Ahead of the company's first quarter results, Roth MKM analyst Darren Aftahi thinks there is money to be made on… [Read More]

1 day ago

Héroux-Devtek is a buy, Desjardins says

Ahead of the company's quarterly results, Desjardins Securities analyst Benoit Poirier likes what he sees from Héroux-Devtek (Héroux-Devtek Stock Quote,… [Read More]

1 day ago

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

2 days ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

2 days ago